4.8 Article

A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 132, Issue 13, Pages -

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI149906

Keywords

-

Funding

  1. National Cancer Institute (NCI) of the NIH [R01-CA160685, R01-CA246437]
  2. American Cancer Society [MBG-21-048-01-MBG, RSG-12-214-01]
  3. Roswell Park Alliance Foundation
  4. NCI Center Support Grant [P30-CA016056]
  5. NIH [R01-CA207757, R01-CA234162, R01-CA23702 7, R01-CA240290]

Ask authors/readers for more resources

The study identified the essential roles of mitochondrial proteins HSP60 and ClpP in the development of prostate cancer, highlighting their importance in maintaining mitochondrial function and promoting cancer cell survival. Inhibition of the interaction between HSP60 and ClpP can suppress PCa growth and progression.
Mitochondrial proteostasis, regulated by the mitochondrial unfolded protein response (UPRmt), is crucial for maintenance of cellular functions and survival. Elevated oxidative and proteotoxic stress in mitochondria must be attenuated by the activation of a ubiquitous UPRmt to promote prostate cancer (PCa) growth. Here we show that the 2 key components of the UPRmt, heat shock protein 60 (HSP60, a mitochondrial chaperonin) and caseinolytic protease P (ClpP, a mitochondrial protease), were required for the development of advanced PCa. HSP60 regulated ClpP expression via c-Myc and physically interacted with ClpP to restore mitochondrial functions that promote cancer cell survival. HSP60 maintained the ATPproducing functions of mitochondria, which activated the beta-catenin pathway and led to the upregulation of c-Myc. We identified a UPRmt inhibitor that blocked HSP60's interaction with ClpP and abrogated survival signaling without altering HSP60's chaperonin function. Disruption of HSP60-ClpP interaction with the UPRmt inhibitor triggered metabolic stress and impeded PCa-promoting signaling. Treatment with the UPRmt inhibitor or genetic ablation of Hsp60 inhibited PCa growth and progression. Together, our findings demonstrate that the HSP60-ClpP-mediated UPRmt is essential for prostate tumorigenesis and the HSP60-ClpP interaction represents a therapeutic vulnerability in PCa.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available